Xiamen Amoytop Biotech Co., Ltd.

Shanghai Stock Exchange 688278.SS

Xiamen Amoytop Biotech Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2023: 0.00

Xiamen Amoytop Biotech Co., Ltd. Debt to Equity Ratio is 0.00 for the year ending December 31, 2023, a -38.98% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Xiamen Amoytop Biotech Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2022 was 0.01, a -68.06% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2021 was 0.02, a 14.59% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2020 was 0.02, a -82.27% change year over year.
Xiamen Amoytop Biotech Co., Ltd. Debt to Equity Ratio for the year ending December 31, 2019 was 0.11, a -23.95% change year over year.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

Shanghai Stock Exchange: 688278.SS

Xiamen Amoytop Biotech Co., Ltd.

CEO	Mr. Li Sun
IPO Date	Jan. 17, 2020
Location	China
Headquarters	No. 330 Wengjiao Road
Employees	1,960
Sector	Healthcare
Industries Biotechnology Chemicals & Advanced Materials Cleaning Supplies Composite Materials Fertilizers Petrochemicals Pharmaceuticals Plastics

Description

Xiamen Amoytop Biotech Co., Ltd. engages in the manufacture, marketing, and sale of recombinant protein drugs using genetic engineering technology in China. It offers formulations, reagents, and APIs, as well as custom-manufacturing services. The company was founded in 1996 and is based in Xiamen, China.

Key trends

Past 5 years